HERTHENA Trademark

Trademark Overview

On Tuesday, July 7, 2020, a trademark application was filed for HERTHENA with the United States Patent and Trademark Office. The USPTO has given the HERTHENA trademark a serial number of 79293761. The federal status of this trademark filing is REGISTERED as of Tuesday, August 10, 2021. This trademark is owned by DAIICHI SANKYO COMPANY, LIMITED. The HERTHENA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Clinical studies and trials of pharmaceuticals for others; providing information on clinical studies and trials of pharmaceuticals
herthena

General Information

Serial Number79293761
Word MarkHERTHENA
Filing DateTuesday, July 7, 2020
Status700 - REGISTERED
Status DateTuesday, August 10, 2021
Registration Number6443546
Registration DateTuesday, August 10, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 25, 2021

Trademark Statements

Goods and ServicesClinical studies and trials of pharmaceuticals for others; providing information on clinical studies and trials of pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 25, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Thursday, September 17, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, September 23, 2020LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, September 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 29, 2020APPLICATION FILING RECEIPT MAILED
Thursday, October 15, 2020ASSIGNED TO EXAMINER
Wednesday, October 21, 2020NON-FINAL ACTION WRITTEN
Thursday, October 22, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, November 12, 2020REFUSAL PROCESSED BY MPU
Thursday, November 12, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, November 29, 2020REFUSAL PROCESSED BY IB
Tuesday, April 20, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 20, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 21, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 22, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 5, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 5, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, May 5, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sunday, May 23, 2021NOTIFICATION PROCESSED BY IB
Tuesday, May 25, 2021PUBLISHED FOR OPPOSITION
Tuesday, May 25, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 10, 2021REGISTERED-PRINCIPAL REGISTER
Wednesday, November 10, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, January 22, 2022FINAL DISPOSITION PROCESSED
Saturday, January 22, 2022FINAL DISPOSITION NOTICE SENT TO IB
Monday, February 14, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Sunday, July 3, 2022NEW REPRESENTATIVE AT IB RECEIVED
Thursday, April 2, 2026NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

herthena clinical trials pharmaceuticals studies information others providing